A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell disease

The most common treatment for patients with sickle cell disease (SCD) is the chemotherapeutic hydroxyurea, a therapy with pleiotropic effects, including increasing fetal hemoglobin (HbF) in red blood cells and reducing adhesion of white blood cells to the vascular endothelium. Hydroxyurea has been p...

Descripción completa

Detalles Bibliográficos
Autores principales: McArthur, James G., Svenstrup, Niels, Chen, Chunsheng, Fricot, Aurelie, Carvalho, Caroline, Nguyen, Julia, Nguyen, Phong, Parachikova, Anna, Abdulla, Fuad, Vercellotti, Gregory M., Hermine, Olivier, Edwards, Dave, Ribeil, Jean-Antoine, Belcher, John D., Maciel, Thiago T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049346/
https://www.ncbi.nlm.nih.gov/pubmed/31147439
http://dx.doi.org/10.3324/haematol.2018.213462

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049346/
https://www.ncbi.nlm.nih.gov/pubmed/31147439
http://dx.doi.org/10.3324/haematol.2018.213462

Ejemplares similares